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Abstract 
Background: Alzheimer’s disease (AD) is associated with unintended weight loss.  We 
examined body composition in early AD and nondemented aging and its relation to 
brain volume and cognition.     
Methods:  Brain magnetic resonance imaging (MRI) and neuropsychological testing 
were performed on nondemented (CDR 0, n=70) and early-stage AD (CDR 0.5 or 1, 
n=70) subjects.  Dual energy x-ray absorptiometry (DEXA) determined whole-body fat 
mass and lean mass.  Body mass index (BMI) was determined from height and weight.  
Linear regression analyses controlling for age and sex assessed the relationship 
between body composition, cognition, and brain volume.   
Results: Lean mass was reduced in early AD compared to nondemented controls 
(F=7.73, p=0.006) after controlling for sex.  Lean mass was associated with whole-brain 
volume (beta=0.20, p<0.001) and white matter volume (beta=0.19, p<0.001) when 
controlling for age and sex.  Lean mass was also associated with global cognitive 
performance (beta=0.12, p=0.007) when controlling for age and sex.  Total body fat and 
percent body fat were not different across groups or related to cognition and brain 
volume.    
Conclusion:   Loss of lean mass is accelerated in AD and associated with brain 
atrophy.  AD and sarcopenia may share common underlying mechanisms or sarcopenia 
may be a direct or indirect consequence of AD pathophysiology.    
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Introduction 
Alzheimer’s disease (AD) is commonly associated with unintended weight loss1 that 
begins years prior to the recognition of AD-related clinical symptoms.2-4  Weight loss in 
those with AD is associated with dementia severity and faster clinical progression.1  AD-
related brain changes including medial temporal lobe atrophy5 and neuropathological 
burden (plaques and tangles)6 are associated with reduced body mass index (BMI) 
suggesting that neurodegenerative processes may contribute to alterations in body 
composition.   
 
Epidemiological studies suggest a complex relationship between body composition and 
cognitive outcomes that may be variable across the age-spectrum.  Obesity in midlife is 
a risk factor for the future development of dementia,7, 8 an observation that is 
strengthened by neuroimaging evidence suggesting that obesity is associated with 
temporal lobe atrophy9, 10 and abnormal spectroscopic measures of brain integrity.11  
Obesity in late-life, however, has been variably associated with dementia risk, with 
some studies reporting a lower dementia risk in overweight and obese older adults12, 13 
perhaps explained by weight loss associated with the preclinical and early stages of 
AD.2-4    
 
Most studies of body composition in dementia and AD are limited by relatively 
nonspecific measures of body composition such as total body weight or BMI rather than 
more specific measures of body fat and muscle mass.   To further examine body 
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composition in AD, we used dual emission x-ray absorptiometry (DEXA) to examine 
group differences in body composition in early-stage AD and nondemented subjects.  
Additionally, we examined predictors of body composition, including examining the 
hypothesis that imaging measures of neurodegeneration (i.e., brain atrophy) would be 
associated with lower BMI, lean mass, and percent body fat.  We also examined 
whether cognitive dysfunction was associated with body composition, expecting that 
cognitive function would be positively correlated with measures of body composition.   
 
Methods 
Sample and Recruitment:  Participants were 60 years and older and either 
nondemented (Clinical Dementia Rating (CDR) 0, n = 70) or diagnosed with early-stage 
AD (CDR 0.5 [n=56] and 1 [n=14]).  Participants were recruited from a referral-based 
memory clinic and by media appeals.  Study exclusions include neurologic disease 
other than AD, diabetes mellitus (defined as a clinical diagnosis and use of an anti-
diabetic agent), history of ischemic heart disease (acute coronary artery event, angina), 
schizophrenia, clinically-significant depressive symptoms, abnormalities in vitamin B12, 
RPR, or thyroid function, use of antipsychotic and investigational medications, and 
significant visual or auditory impairment, systemic illness, or orthopedic issues that 
could impair completion of the study.  We have previously reported results on sub-
samples of this cohort.14-16 
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Clinical Assessment:  All subjects were evaluated using a semi-structured interview of 
the participant and a knowledgeable collateral source to determine the presence or 
absence of dementia, and its severity if present, using the Clinical Dementia Rating 
(CDR).17  Diagnostic criteria for AD require the gradual onset and progression of 
impairment in memory and in at least one other cognitive and functional domain.18 
These diagnostic methods have an accuracy for AD of 93%19 and sensitively detect the 
earliest stages of AD by focusing on intra-individual change rather than comparison with 
group norms.20   Additionally, they accurately identify the subset of individuals meeting 
criteria for MCI who have early stage AD.21  A global CDR score is derived from 
individual ratings in each domain with CDR 0 indicating no dementia, CDR 0.5 very mild 
dementia, CDR 1 mild dementia.  Subjects with moderate (CDR 2) or severe (CDR 3) 
dementia were not enrolled in the study.   The CDR sum of boxes was used as a 
measure of dementia severity.   
 
Medications, past medical history, education, and demographic information were 
collected from the collateral source by a nurse clinician. A standard physical and 
neurological examination was performed to assess abnormalities in visual fields, cranial 
nerves, motor strength, sensation, reflexes, plantar responses, coordination, praxis, and 
gait.  Functional activity level was estimated using the Mild Cognitive Impairment 
Activities of Daily Living Scale (MCI-ADL) scale with information collected from the 
collateral source.22 The scale evaluates 18 domains and ranges from zero (worst 
performance) to 57 (best performance). 
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Neuropsychological Assessment:  A trained psychometrician administered a standard 
psychometric battery to all participants as previously described.14-16  The battery 
included standard measures of memory (WMS-R Logical Memory I and II, Free and 
Cued Selective Reminding Task), language (Boston Naming Test – 15 item), working 
memory (WMS III Digit Span Forwards and Backwards, WAIS Letter-number 
sequencing), executive function (Trailmaking A and B, Verbal Fluency (animals, fruits 
and vegetables), and Stroop Color-Word Test), and visuospatial ability (WAIS Block 
Design).  Cognitive performance scores for each test were converted to z-scores (with 
higher scores representing better performance) based on the mean and standard 
deviation of nondemented subjects.  The mean of each participant’s z-scores was 
determined to create an index of global cognitive performance.  The mini-mental status 
examination (MMSE) was also administered as a measure of global cognition. 
 
Body Composition: Dual energy x-ray absorptiometry (DEXA; Lunar Corp.) was used to 
determine regional and total body measures of lean mass and fat mass.  Percent body 
fat represents the percent of total body mass (determined by DEXA) composed of fat 
(i.e., total body fat / total body mass).  We utilized total body weight determined by 
DEXA.  DEXA determined weight was highly correlated with our manually measured (by 
scale) body weight (r=0.999, p<0.001) yet minimizes the influence of clothing.  Height 
was measured using a standard stadiometer.  Body mass index (BMI) was determined 
by dividing total body weight (in kg) by the square of height in meters (m2).  Total lean 
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mass was also normalized by height (lean mass index) by dividing total body lean mass 
(in kg) by the square of height (m2).   
 
Neuroimaging:  Structural MRI was obtained on all participants using a Siemens 3.0 
Tesla Allegra MRI scanner at the Hoglund Brain Imaging Center.  High-resolution T1-
weighted anatomic images were acquired to provide detailed gross anatomy with high 
gray-white matter contrast (MP-RAGE; 1x1x1mm3 voxels; TR=2500, TE=4.38, TI=1100, 
FOV 256X256mm2 with 18% oversample, 1mm slice thickness, flip angle=8 degrees).  
Normalized Whole Brain Volume was computed for each image session using a 
validated set of imaging tools from the FMRIB Software Library (FSL; 
www.fmrib.ox.ac.uk/fsl) as previously described15 utilizing the Laboratory of 
Neuroimaging Pipeline (University of California Los Angeles, 
www.pipeline.loni.ucla.edu). Briefly, the images were pre-processed and skull-stripped 
using Brain Extraction Tool. The skull-stripped images were then segmented into white 
matter, gray matter, and cerebrospinal fluid using FMRIB’s Automated Segmentation 
Tool (FAST) by registering them to the Montreal Neuroimaging Institute avg152 
template.  Normalized volumes for white matter, gray matter, and whole brain (sum of 
white and gray matter) were calculated by dividing each by the total intracranial volume 
(the sum of white, gray, and cerebrospinal fluid volumes) and expressed as the percent 
of total intracranial volume.  Normalized brain volumes minimize sex differences and 
produce an estimate of brain atrophy.   
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Other Clinical Measures: We also examined potential covariates that may mediate brain 
and body composition relationships including habitual level of physical activity, 
depressive symptoms, frailty, and laboratory assessments of insulin, lipids, inflammation 
and apolipoprotein E4 allele status as previously described.14-16   Each participant’s 
level of habitual physical activity was estimated using the Physical Activity Scale in the 
Elderly (PASE), a reliable and valid measure of physical activity and physical function 
developed specifically for older individuals.23  The PASE provides an estimate of an 
individual’s level of physical activity within the last seven days by assessing the 
frequency and duration of participation in activities such as walking, yard work, 
household activities, and sports and recreational activities such as golf, tennis, dancing, 
jogging, weight lifting, etc.  The PASE is administered to both the subject and the study 
partner.  For individuals with AD, data collected from the study partner was used in the 
analyses.  We assessed peripheral insulin levels (by radioimmunoassay, Diagnostic 
Systems Laboratories, Webster, TX) using a standard 14-sample, three-hour 
intravenous glucose tolerance test performed at 8:30AM after a 12-hour overnight fast, 
as previously described.16  Total 3-hour area-under-the-curves (AUC) for glucose and 
insulin served as overall indices for glucose and insulin levels.  The Physical 
Performance Test (PPT) was used as a measure of physical performance and frailty.24  
Fasting venous blood samples were assessed using commercial enzymatic assays for 
total cholesterol (Diagnostic Chemicals, Ltd.). Highly-sensitive C-reactive protein (CRP) 
was determined in fasting blood by turbidimetric assay (Roche Diagnostics Systems).   
 
12 
 
Statistical Analyses: Analyses were conducted using SPSS 16.0.  Continuous variables 
were summarized by means and standard deviations and categorical variables were 
summarized by frequency and percent.  The Student’s T-test was used to compare 
continuous demographic and imaging variables in early AD and nondemented groups. A 
chi square test was used to compare categorical variables.  Pearson’s correlation 
coefficients were calculated to assess simple relationships between variables.  Linear 
regression was used to examine the relationship of variables of interest (i.e., whole 
brain volume, cognition) with body composition (i.e., BMI, lean mass, and fat mass as 
dependent variables).  All analyses were controlled for age and sex.  Secondary 
analyses controlled for additional covariates that correlated with body composition (i.e., 
dementia status, physical activity, insulin and glucose levels [3-hour AUC], and CRP).  
Additional models examined for the presence of interactions (e.g., dementia x sex).  A 
final exploratory multiple linear regression model examined the influence of all variables 
of interest and covariates on body composition. Age and sex were forced into the model 
with covariates entered as stepwise regression retaining variables with p<0.05.   
 
Results 
Descriptives 
Table 1 summarizes the characteristics of the non-demented and early AD groups.  The 
mean age of the cohort (n=140) was 74.1 (6.8) years with no difference between non-
demented and early stage AD groups.  Individuals with early AD had a mean MMSE 
score of 26.0 (out of 30 points), indicating mild global cognitive dysfunction.  Early-AD 
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participants demonstrated impairments in daily function, lower whole brain volume, and 
reduced habitual levels of physical activity.   
 
To identify potentially important covariates, we examined the relationship of body 
composition measures with age and other clinical measures.  Age was inversely 
associated with total lean mass (beta==-0.18, p<0.001) and lean mass index (beta=-
0.014, p=0.02) when controlling for sex.   Controlling for age and sex, total lean mass 
was associated with habitual physical activity (beta=0.14, p<0.001) and insulin AUC 
(beta=0.11, p=0.02).  Percent body fat was associated with insulin AUC (beta=0.28, 
p<0.001), glucose AUC (beta=0.19, p=0.007), and CRP (beta=0.17, p=0.01) when 
controlling for age and sex.  There were no ApoE4-related differences in total lean mass 
and percent body fat.  Given these associations, we performed all analyses controlling 
for age and sex and secondary analyses controlling for potential confounding by 
physical activity, CRP, insulin, and glucose.  
 
Body Composition in AD and Nondemented Subjects 
Total lean mass was reduced in individuals with early AD compared to nondemented 
controls after controlling for known sex differences in lean mass (F=7.73, p=0.006).  
There were no dementia group x sex interactions, suggesting AD-related differences in 
lean mass were not different in men and women. Normalizing lean mass for height (lean 
mass index) slightly attenuated the differences in lean mass across early AD and 
nondemented groups (p=0.09), likely driven by lower height in the men with early AD 
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compared to nondemented men (table 2).  BMI, body weight and body fat measures 
were not different across dementia groups.  Given known differences in body 
composition in men and women, body composition data is presented in table 2 for the 
overall group and stratified by sex. 
 
Brain Atrophy and Body Composition 
We examined the association of brain atrophy measures with body composition 
controlling for age and sex.  Whole brain volume was predictive of total lean mass 
(beta=0.20, p<0.001) and lean mass index (0.19, p=0.009).  Controlling for dementia 
status and additional covariates of physical activity, CRP, and insulin and glucose levels 
(3-hour AUC) did not alter the results.  Whole brain volume was also associated with 
BMI (beta = 0.20, p=0.05) but this relationship was attenuated when controlling for 
dementia status (p=0.11).  Whole brain volume was not associated with total body fat 
(beta=0.14, p=0.21) and percent body fat (beta=0.01, p=0.89).    There were no 
dementia status x whole brain volume or sex x whole brain volume interactions, 
suggesting that the positive relationship between whole brain volume and body 
composition was similar in AD vs. nondemented and men vs. women.   
 
We next examined the relationship between components of whole brain volume (gray 
and white matter volume) and body composition when controlling for age and sex.  
White matter volume was associated with lean mass (beta=0.19, p<0.001), lean mass 
index (beta=0.23, p<0.001), and BMI (beta=0.23, p=0.01) but not total body fat or 
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percent body fat.   These associations were unchanged when controlling for dementia 
status and additional covariates of physical activity, CRP, insulin and glucose 
measures.  Gray matter volume was not associated with any measures of body 
composition. 
 
We next examined an overall model that included all variables of interest (whole brain 
volume, global cognition, dementia status) and covariates (age, sex, physical activity, 
CRP, and insulin and glucose) to assess which variables were most strongly related to 
lean mass.  Age and sex were forced into the model (step 1) with all covariates 
assessed in step 2 using stepwise regression.  In this model, whole brain volume 
(beta=0.13, p=0.01), insulin (3-hour AUC; beta=0.10, p=0.02), and physical activity level 
(beta=0.13, p=0.01) were each independently predictive of lean mass.   
 
Cognitive Performance and Body Composition 
We next assessed the relationship of global measures of cognitive performance (global 
cognitive index and MMSE) with body composition controlling for age and sex.  Total 
lean mass was associated with global cognitive performance (beta=0.12, p=0.007) and 
MMSE (beta=0.11, p=0.009).  As global cognition is a composite measure of 
performance on individual cognitive tests, we next assessed the relationship of lean 
mass on performance of individual cognitive tests controlling for age and sex.  Lean 
mass was associated with performance on logical memory I (beta=0.12, p=0.007), 
logical memory II (beta=0.09, p=0.04), trailmaking A (beta=-0.09, p=0.05), trailmaking B 
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(beta=-0.11, p=0.01), category fluency (beta=0.09, p=0.05), block design (beta=0.13, 
p=0.005), and digit span forward (beta=0.10, p=0.03). There were no dementia status x 
cognitive performance interactions in predicting lean mass or lean mass index 
suggesting that the relationship between lean mass and cognition is similar in AD and 
nondemented participants. Additional analyses controlling for dementia status resulted 
in attenuation of these results, suggesting that group differences in cognition and lean 
mass were driving the results.  Total body fat and percent body fat were not related to 
global cognitive performance in any analyses.   
 
Discussion 
Our findings are consistent with prior reports that alterations in body composition are 
apparent in the earliest clinical stages of AD.2-4   Our study extends these reports by 
suggesting that AD-related alterations in body composition may be predominantly 
related to loss of lean mass (i.e., sarcopenia), consistent with at least one large, 
epidemiological study that found an association between cognitive impairment and 
reduced muscle mass.25  Although measures of adiposity have been linked with an 
increased risk for AD,13 we found no relationship of total body fat measures with brain 
volume, cognition, or dementia status.  The study design (cross-sectional, case-control) 
limits our ability to infer causal relationships but our data suggests that loss of lean 
mass (i.e., sarcopenia) may be accelerated in the earliest stages of AD.     
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We observed a direct correlation between whole brain volume (an estimate of brain 
atrophy) and lean mass suggesting that brain atrophy and loss of muscle mass may co-
occur.  Our data are consistent with other studies suggesting that brain pathology may 
contribute to decline in body composition6 perhaps by disrupting CNS regulation of 
energy metabolism and food intake.26  Brain atrophy is considered a neuroimaging 
marker reflective of AD pathology,27 although we observed a strong relationship 
between lean mass and white matter volume, rather than gray matter volume which is 
more strongly linked with neurodegeneration.  This, and the similar lean mass – brain 
volume relationship observed in nondemented and AD participants, suggests that 
mechanisms other than AD processes may underlie these relationships.   
 
Additionally, we observed modest correlations between lean mass and cognitive 
performance.  Previous studies have demonstrated that higher BMI is associated with 
better cognitive performance28 and less cognitive decline;29  thus, our results extend 
these studies by suggesting that lean mass, rather than adiposity, may be a more 
specific factor relating body composition with cognitive outcomes in older adults.     
 
Our observations also suggest that AD and sarcopenia may share common underlying 
mechanisms.  Sarcopenia in normal aging is most strongly associated with age-related 
reductions in physical activity30  and alterations in anabolic and inflammatory stimuli.31  
AD is associated with reduced physical activity14 and systemic anabolic and 
inflammatory abnormalities that are implicated in sarcopenia.32-34   While our measures 
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of anabolic and inflammatory processes are limited in this study, we observed a 
correlation between lean mass and insulin, a well-known anabolic hormone35 that may 
have neurotrophic36 and neuroprotective37 affects.  We previously  reported that insulin 
levels are associated with cognition and brain volume in early AD and that this 
association is strongest for white matter.16  Additionally, insulin signaling preferentially 
affects the development of white matter structures.38  Thus, our observation that white 
matter volume, lean mass, and insulin levels are inter-related suggests that loss of 
anabolic support to both muscle and brain may be a potential mechanism underlying the 
observed relationships.    
 
Individuals with early AD had reduced physical activity levels compared to the 
nondemented cohort.  Additionally, an individual’s physical activity level was predictive 
of lean mass, with lower physical activity associated with less lean mass.  These 
observations suggest that the AD clinical syndrome may indirectly influence lean mass 
through associated reductions in physical activity.  Physical activity and exercise have 
well-described anti-inflammatory39 and anabolic effects and result in increased lean 
mass.  Accumulating animal and human studies link exercise and fitness with brain 
health15, 40-42 although the mechanisms relating exercise with brain health remain 
imprecisely defined.   While the cross-sectional, case-control design limits the ability to 
infer causality, these data suggest that factors associated with the preservation lean 
muscle, such as exercise, may attenuate structural and functional brain changes 
associated with AD and aging.   
19 
 
 
 
The current study is limited by its cross-sectional design and relatively small sample 
size.  We utilized validated clinical methods for diagnosing the earliest stages of AD 
although these methods are imperfect in predicting AD pathology.  Additionally, study 
participants were part of a convenience sample which limits generalizability and may 
have introduced sampling bias that could impact the results.  Further longitudinal and 
interventional studies will be necessary to more precisely define the nature and 
mechanisms of body composition changes in AD.   Our data suggest that loss of lean 
mass may be accelerated in AD perhaps through underlying mechanisms common to 
both AD and sarcopenia or as a direct or indirect consequence of AD pathophysiology.   
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Table 1: Sample Characteristics 
 Nondemented  Early AD   
 (n = 70 ) (n = 70) p value 
Age, years 73.3 (7.3) 74.9 (6.7) 0.17  
Education, years 16.5 (2.7) 15.2 (3.3) 0.01 
Female % (n) 57.2 (40) 58.6 (41) 0.86 
Apolipoprotein E4 Carrier % (n) 27.9 (19) 59.1 (39) <0.001 
 
MMSE 29.4 (0.8)  26.0 (3.5) <0.001 
Global Cognitive Performance, Z-score  0.1 (0.6) -1.7 (1.1) <0.001 
Activities of Daily Living 48.5 (3.3) 40.2 (7.8) <0.001 
Geriatric Depression Scale 0.49 (0.79) 3.3 (2.9) <0.001 
 
Whole Brain Volume, %ICV 78.0 (2.9) 75.3 (3.3) <0.001 
White Matter Volume, %ICV 35.0 (1.9) 34.6 (2.4) 0.32 
Gray Matter Volume, %ICV 43.0 (2.5) 40.6 (2.4) <0.001 
 
Physical Activity Level (PASE Score) 130.4 (51.8) 88.9 (56.7) <0.001  
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Physical Performance Test 30.5 (3.4) 27.6 (3.9) <0.001 
Total Cholesterol (ml/dl) 182.6 (34.0) 188.1 (37.4) 0.37 
C-reactive Protein (mg/L) 2.3 (2.4) 1.8 (1.5) 0.11 
Insulin Area-Under-the-Curve** 2540 (1361) 2903 (1747) 0.18 
Glucose Area-Under-the-Curve** 22475 (2851) 23049 (4541) 0.38 
 
*  Peak oxygen consumption normalized by total lean mass.  
 
**Area-under-the-curve generated from a three-hour intravenous glucose tolerance test. 
 
All data represent means (SD) except when otherwise noted. 
 
MMSE: Mini-Mental State Examination; %ICV: percent intracranial volume 
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Table 2:  Body Composition in Early AD compared to Nondemented Controls  
 
 Nondemented  Early AD  p-value 
Body Mass Index  
 Overall* 25.7 (3.6) 25.0 (3.9) 0.29 
 Men 25.7 (3.6) 25.6 (3.5) 0.94  
 Women 25.7 (3.7) 24.5 (4.2) 0.20 
 
Body Weight (kg)  
 Overall* 70.5 (13.4) 66.7 (12.5) 0.06 
 Men 78.4 (13.0) 74.4 (11.4) 0.22  
 Women 64.5 (10.5) 61.1 (10.1) 0.14 
 
Total Lean Mass (kg)  
 Overall* 44.6 (10.4) 41.9 (9.3) 0.009 
 Men 54.6 (7.0) 51.5 (5.9) 0.07  
 Women 37.1 (4.5) 35.2 (3.5) 0.03 
 
Lean Mass Index (kg/m2)  
 Overall* 15.5 (2.0) 15.0 (2.2) 0.09 
 Men 17.2 (1.6) 17.0 (1.7) 0.70  
 Women  14.2 (1.3) 13.6 (1.3) 0.03 
 
  
23 
 
Height (cm)  
 Overall* 169.6 (11.2) 166.2 (9.1) 0.07 
 Men 178.3 (8.3) 174.0 (7.0) 0.04  
 Women 161.4 (6.6) 160.8 (6.1) 0.69 
 
Fat Mass (kg)  
 Overall* 25.8 (8.3) 24.7 (8.7) 0.41 
 Men 23.8 (8.5) 22.8 (8.8) 0.67  
 Women 27.4 (7.8) 25.9 (8.4) 0.43 
 
Percent Body Fat  
 Overall* 36.8 (9.0) 36.7 (9.9) 0.87 
 Men 30.0 (7.5) 30.0 (8.5) 0.99  
 Women 41.8 (6.3) 41.4 (7.9) 0.81 
 
All data represent means (SD).   
*Group comparison by general linear model controlling for sex; all other group 
comparisons were tested using Student’s t-test.  
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Figure 1:  Relationship between Lean Mass and Whole Brain Volume  
 
 
Figure Legend:  Whole brain volume is positively associated with lean mass in early 
AD and nondemented controls.  Whole brain volume is normalized to account for 
differences in head size and provide an estimate of brain atrophy.  For illustrative 
purposes in the figure, lean mass was adjusted for gender and age and presented in 
standardized units [Z].  This positive association was not different across AD and 
nondemented groups and was independent of age, gender, dementia severity, 
inflammation, insulin, and glucose measures.        
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